G
Graham Byrnes
Researcher at International Agency for Research on Cancer
Publications - 170
Citations - 17260
Graham Byrnes is an academic researcher from International Agency for Research on Cancer. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 66, co-authored 169 publications receiving 15329 citations. Previous affiliations of Graham Byrnes include Utrecht University & University of Melbourne.
Papers
More filters
Journal ArticleDOI
Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians
John D. Mathews,Anna V. Forsythe,Zoe Brady,Martin W Butler,Stacy Goergen,Graham Byrnes,Graham G. Giles,Anthony Wallace,Philip R Anderson,Philip R Anderson,Tenniel Guiver,Paul McGale,Timothy M. Cain,James G. Dowty,Adrian Bickerstaffe,Sarah C. Darby +15 more
TL;DR: The increased incidence of cancer after CT scan exposure in this cohort was mostly due to irradiation, and future CT scans should be limited to situations where there is a definite clinical indication, with every scan optimised to provide a diagnostic CT image at the lowest possible radiation dose.
Journal ArticleDOI
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
Stephen M. Davis,Geoffrey A. Donnan,Mark W Parsons,Christopher R Levi,Kenneth Butcher,André Peeters,P. Alan Barber,Christopher F. Bladin,Deidre A. De Silva,Graham Byrnes,Jonathan B. Chalk,John N. Fink,Thomas E. Kimber,David Schultz,Peter J. Hand,Judith Frayne,Graeme J. Hankey,Keith W. Muir,Richard P. Gerraty,Brian M. Tress,Patricia Desmond +20 more
TL;DR: Alteplase was non-significantly associated with lower infarct growth and significantly associated with increased reperfusion in patients who had mismatch, and phase III trials beyond 3 h after treatment are warranted.
Journal Article
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
Stephen M. Davis,Geoffrey A. Donnan,Mark W Parsons,Christopher R Levi,Kenneth Butcher,André Peeters,Peter Barber,Christopher F. Bladin,Deidre A De Silva,Graham Byrnes,Jonathan B Chalk,John N. Fink,Thomas E. Kimber,David Schultz,Peter J. Hand,Judith Frayne,Graeme J. Hankey,Keith W. Muir,Richard P. Gerraty,Brian M. Tress,Patricia Desmond +20 more
TL;DR: In this paper, Alteplase was shown to promote reperfusion and attenuate infarct growth in patients who have a mismatch in perfusion-weighted MRI (PWI) and diffusion weighted MRI (DWI).
Journal ArticleDOI
Global burden of cancer attributable to high body-mass index in 2012: a population-based study
Melina Arnold,Nirmala Pandeya,Graham Byrnes,Andrew G Renehan,Gretchen A Stevens,Majid Ezzati,Jacques Ferlay,J. Jaime Miranda,Isabelle Romieu,Rajesh Dikshit,David Forman,Isabelle Soerjomataram +11 more
TL;DR: The continuation of current patterns of population weight gain will lead to continuing increases in the future burden of cancer, and the need for a global effort to abate the increasing numbers of people with high BMI is emphasised.
Journal ArticleDOI
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.
Liacine Bouaoun,Dmitriy Sonkin,Maude Ardin,Monica Hollstein,Monica Hollstein,Graham Byrnes,Jiri Zavadil,Magali Olivier +7 more
TL;DR: This analysis showed that IARC has more TP53 somatic mutation data than genomic repositories (29,000 vs. 4,000), but the more complete screening achieved by genomic studies highlighted some overlooked facts about TP53 mutations.